Eftersom deferiprone kan forbindes med neutropeni og agranulocytose, bør behandling af patienter med svækket immunforsvar ikke indledes, medmindre de mulige fordele overstiger de mulige risici.
Given that deferiprone can be associated with neutropenia and agranulocytosis, therapy in immune compromised patients should not be initiated unless potential benefits outweigh potential risks.